Loading organizations...
Based in Philadelphia, Pennsylvania, Bainbridge Health is a healthcare technology company that provides a cloud-based software platform to analyze medication data and infusion records for large health systems. The enterprise software aggregates data from unconventional clinical sources to help hospital pharmacies standardize dosing, prevent medication errors, and decrease supply chain waste. Operating on a B2B software subscription model, the company currently serves more than 800 hospitals and 150,000 hospital beds across 46 states while processing over three billion historical infusion records. Backed by institutional investors such as the Children’s Hospital of Philadelphia, FCA Venture Partners, and Ben Franklin Technology Partners, the business has raised $6.3 million in total funding and reached a $16.35 million valuation. Originating as a clinical research spin-off, Bainbridge Health was founded in 2016 by Joseph Kaupp, Sean O’Neill, and Sam Wilson.
Bainbridge Health has raised $5.0M across 4 funding rounds.
Bainbridge Health has raised $5.0M in total across 4 funding rounds.
Bainbridge Health is a Philadelphia-based healthcare technology company founded in 2016 as a spinout from the Children's Hospital of Philadelphia (CHOP). It builds Med O.S.®, a data platform that processes pharmacy and medication data from disparate sources to deliver actionable insights, reducing errors, waste, and inefficiencies in hospitals and life sciences organizations.[1][2][3][4] Serving over 500 hospitals across 41 states, it targets pharmacy leaders, clinicians, and supply chain teams, solving problems like medication errors, drug waste from mismatched packaging, non-compliance with protocols, and time-intensive data analysis—achieving results such as 70% alert reductions, 50% override cuts, and 25% lower controlled substance dispensing.[1][3] With $6.3 million raised and rapid growth, Bainbridge aims to reach 1,000 hospitals by end-2025 and 50% of the US market soon after, leveraging its network for benchmarking and best practices.[3]
Bainbridge Health emerged from over a decade of research in Philadelphia's healthcare ecosystem, starting as a collaboration between pharmacy and medication safety departments at a large local health system, specifically spinning out from CHOP.[3][4] Founders Joseph Kaupp (CEO), Sean O’Neill, and Sam Wilson—clinicians and data experts—identified a core frustration: clinicians spent 80% of time mining data and only 20% acting on it, despite abundant analytics tools.[4][5] The idea crystallized around flipping this by providing "answers to the test" via real-world medication data, informed by ground-truth hospital experience and network benchmarking.[2][4] Early traction came from CHOP and partners like Ben Franklin Technology Partners, evolving from local innovation to nationwide scale serving 500+ hospitals, bolstered by the National Infusion Collaborative with Purdue University's Regenstrief Center.[2][3]
Bainbridge rides the healthcare data interoperability and AI-driven efficiency wave, amid rising drug costs, staffing shortages, and regulatory pressures for medication safety—exacerbated by fragmented EHRs, pumps, and supply chains generating underutilized data.[2][3][5] Timing aligns with post-pandemic scrutiny on waste (e.g., unused meds in oversized bags) and value-based care, where Bainbridge's network effects provide evidence-based proof to overcome clinician skepticism.[3][4] It influences the ecosystem by standardizing practices through benchmarking, fostering collaborations like the National Infusion Collaborative, and enabling suppliers to develop targeted ready-to-use meds—potentially reducing national hospital waste as it scales to half the US market.[1][2][3]
Bainbridge Health is poised for explosive growth, targeting 1,000+ hospitals by late 2025 and 50% US penetration shortly after, fueled by pipeline momentum and expanding life sciences tools.[3] Trends like AI-enhanced analytics, regulatory pushes for smart pumps/EHR integration, and supply chain resilience will amplify its edge, especially as networks grow for richer benchmarking. Its clinician-first model could evolve influence from operator to ecosystem shaper, standardizing pharmacy practices nationwide and cutting billions in waste—proving that unlocking medication data truly delivers the interventions clinicians crave.[1][2][4]
Bainbridge Health has raised $5.0M across 4 funding rounds. Most recently, it raised $1.6M Other Equity in June 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 18, 2018 | $1.6M Venture Round | — | BioAdvance, Chestnut Street Ventures, Children's Hospital OF Philadelphia | Announced |
| Jun 1, 2018 | $2M Seed | — | BioAdvance, NEW Stack Ventures, Space Capital, Alexander Lavin, Paul Holliman | Announced |
| Apr 17, 2017 | $1.3M Seed | — | — | Announced |
| Oct 3, 2016 | $54K Venture Round | BioAdvance | — | Announced |
Bainbridge Health has raised $5.0M in total across 4 funding rounds.
Bainbridge Health's investors include BioAdvance, Chestnut Street Ventures, Children's Hospital of Philadelphia, New Stack Ventures, Space Capital, Alexander Lavin, Paul Holliman.
